Michael Nuoqing Yi
Chief Investment Officer bei Hillhouse Investment Management Ltd. (Invest)
Profil
Michael Nuoqing Yi has worked as a Director at Sironax Ltd.
and as a Co-Chief Investment Officer at Hillhouse Investment Management Ltd.
(Invest).
Aktive Positionen von Michael Nuoqing Yi
| Unternehmen | Position | Beginn |
|---|---|---|
Hillhouse Investment Management Ltd. (Invest)
 Hillhouse Investment Management Ltd. (Invest) Investment ManagersFinance Hillhouse Capital Management Ltd. (Hillhouse Capital) is a Private Equity/Venture Capital firm, a subsidiary of Hillhouse Capital Group Ltd. founded in 2005 by Lei Zhang. The firm is headquartered in Hong Kong. | Chief Investment Officer | - |
Sironax Ltd.
 Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Hillhouse Investment Management Ltd. (Invest)
Hillhouse Investment Management Ltd. (Invest) Investment ManagersFinance Hillhouse Capital Management Ltd. (Hillhouse Capital) is a Private Equity/Venture Capital firm, a subsidiary of Hillhouse Capital Group Ltd. founded in 2005 by Lei Zhang. The firm is headquartered in Hong Kong. | Finance |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |
